JP2020512292A - リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 - Google Patents

リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 Download PDF

Info

Publication number
JP2020512292A
JP2020512292A JP2019533167A JP2019533167A JP2020512292A JP 2020512292 A JP2020512292 A JP 2020512292A JP 2019533167 A JP2019533167 A JP 2019533167A JP 2019533167 A JP2019533167 A JP 2019533167A JP 2020512292 A JP2020512292 A JP 2020512292A
Authority
JP
Japan
Prior art keywords
linaclotide
week
pain
composition
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512292A5 (https=
Inventor
アハマド ハシャシュ，
アハマド ハシャシュ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of JP2020512292A publication Critical patent/JP2020512292A/ja
Publication of JP2020512292A5 publication Critical patent/JP2020512292A5/ja
Priority to JP2022073214A priority Critical patent/JP2022093472A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019533167A 2016-12-21 2017-12-21 リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 Pending JP2020512292A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022073214A JP2022093472A (ja) 2016-12-21 2022-04-27 リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437566P 2016-12-21 2016-12-21
US62/437,566 2016-12-21
PCT/US2017/067814 WO2018119191A1 (en) 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022073214A Division JP2022093472A (ja) 2016-12-21 2022-04-27 リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法

Publications (2)

Publication Number Publication Date
JP2020512292A true JP2020512292A (ja) 2020-04-23
JP2020512292A5 JP2020512292A5 (https=) 2021-02-04

Family

ID=61022424

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019533167A Pending JP2020512292A (ja) 2016-12-21 2017-12-21 リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法
JP2022073214A Pending JP2022093472A (ja) 2016-12-21 2022-04-27 リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022073214A Pending JP2022093472A (ja) 2016-12-21 2022-04-27 リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法

Country Status (10)

Country Link
EP (1) EP3558337A1 (https=)
JP (2) JP2020512292A (https=)
CN (1) CN110475564A (https=)
AU (1) AU2017379082A1 (https=)
BR (1) BR112019012689A2 (https=)
CA (1) CA3048195A1 (https=)
EA (1) EA201991531A1 (https=)
MA (1) MA47112A (https=)
MX (2) MX2019007574A (https=)
WO (1) WO2018119191A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220241367A1 (en) * 2019-06-10 2022-08-04 Ironwood Pharmaceutical, Inc. Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
IL313184A (en) * 2021-11-29 2024-07-01 Ironwood Pharmaceuticals Inc Pharmaceutical compositions for the treatment of visceral pain
WO2023196821A2 (en) * 2022-04-04 2023-10-12 Thomas Jefferson University Targeting neuropod cell gucy2c to control visceral pain and appetite

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197042A1 (en) * 2015-06-05 2016-12-08 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN117530912A (zh) 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
WO2011020054A1 (en) * 2009-08-13 2011-02-17 Ironwood Pharmaceuticals Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
DK2603232T3 (da) * 2010-08-11 2019-12-09 Ironwood Pharmaceuticals Inc Stabile formuleringer af linaclotid
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP6716255B2 (ja) * 2013-01-15 2020-07-01 アイロンウッド ファーマシューティカルズ，インコーポレーテッドＩｒｏｎｗｏｏｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197042A1 (en) * 2015-06-05 2016-12-08 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, 2017.4, VOL.152, NO.5, SUPPL.1, PP.S1314-S1315, JPN6021042902, ISSN: 0004626070 *
STUDY NCT02559206 SUBMITTED DATE: JULY 22, 2016 (V3)，CLINICALTRIALS.GOV ARCHIVE[ONLINE]，2016年7月2, JPN6021042901, ISSN: 0004771781 *
THE AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020.10, VOL.116, PP.354-361, JPN6021042903, ISSN: 0004626071 *

Also Published As

Publication number Publication date
BR112019012689A2 (pt) 2019-11-19
WO2018119191A1 (en) 2018-06-28
EP3558337A1 (en) 2019-10-30
JP2022093472A (ja) 2022-06-23
CN110475564A (zh) 2019-11-19
MX2023008839A (es) 2023-08-14
EA201991531A1 (ru) 2019-11-29
CA3048195A1 (en) 2018-06-28
MA47112A (fr) 2019-10-30
MX2019007574A (es) 2019-09-04
AU2017379082A1 (en) 2019-07-04
WO2018119191A9 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
JP7483656B2 (ja) リナクロチドの遅延放出組成物
JP2022093472A (ja) リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法
US20220241367A1 (en) Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
US20250073301A1 (en) Delayed Release Compositions of Linaclotide
HK40081509A (en) Delayed release compositions of linaclotide
HK40051190A (en) Delayed release compositions of linaclotide
HK40017265A (en) Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide
BR112016013419B1 (pt) Composições de liberação retardada compreendendo um comprimido com revestimento entérico, forma de dosagem unitária e uso
HK1237651A1 (en) Delayed release compositions of linaclotide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220516